Showing results (61-70 of 160) with videos related to
Sort By:
Pageof 16
Molecular Cancer|February 20, 2018
Third generation EGFR TKIs: current data and future directionsChee-Seng Tan, Nesaretnam Barr Kumarakulasinghe, Yi-Qing Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patientsLai-San Tham, Lingzhi Wang, Ross A Soo, et al.Frontiers in Immunology|July 7, 2020
Eomes Expression Defines Group 1 Innate Lymphoid Cells During Metastasis in Human and MouseRiva Verma, Jun Zhi Er, Ren Wei Pu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2021
Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational StudyAbdul Rahman Jazieh, Huseyin Cem Onal, Daniel Shao Weng Tan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancerAlvin S Wong, Richie Soong, Serena Bee-Kee Seah, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 16, 2024
Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR StudyRoss A Soo, Thanyanan Reungwetwattana, Herman Andres Perroud, et al.Future Oncology (London, England)|August 29, 2020
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.Cancer Chemotherapy and Pharmacology|May 17, 2003
Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group studyRoss A Soo, Hong L Lim, Ling Z Wang, et al.JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC TrialJames Chih-Hsin Yang, Tony S K Mok, Shun Lu, et al.International Journal of Cancer|September 25, 2021
Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patientsYiqing Huang, Yu Yang Soon, Folefac Aminkeng, et al.Pageof 16